COSYCHEM's Pre-B Round Financing Led by Cohesive Energy Investment.
On May 13th, Tianjin COSYCHEM Technology Co., Ltd. (hereinafter referred to as "COSYCHEM") announced the successful completion of a Pre-B round financing exceeding CNY 100 million. This round was exclusively invested by Cohesive Energy Investment, with DAS Capital serving as the exclusive financial advisor. The new round of financing will mainly be used for the development and commercial promotion of biological technology chemical raw materials and downstream applications, including nucleic acid drugs, delivery systems, and in vitro diagnostics.
COSYCHEM is committed to becoming the most trusted partner for life science enterprises, always adhering to innovation leadership, actively promoting the deep integration of government, industry, academia, and research, and expanding the boundaries of technology and products to form a highly relevant integrated business model. With years of technical accumulation, COSYCHEM's various technology platforms are in a leading position in their respective fields, having successively established a synthetic technology general platform, a cross-technology application platform, a gene therapy delivery platform, a nucleic acid drug discovery platform, an IVD technology service platform, and an intellectual property operation platform.
At the same time, COSYCHEM has achieved industrialization of new technologies and breakthroughs in source technology innovation and industry demand in aspects such as the discovery of nucleic acid drug lead compounds, R&D validation, testing platforms, core raw material production, and analytical quality control. Ultimately, it aims to become a leading domestic and world-class supplier of raw materials for biological technology services.
COSYCHEM has completed the construction of a delivery technology platform in the field of gene therapy, aiming to provide customers with comprehensive solutions for targeted drug delivery. In the field of small nucleic acid drug delivery systems, COSYCHEM can provide a variety of GalNAc structure custom synthesis services. It has rich experience in R&D and synthesis, the ability to deliver at scales above kilograms, and a strict and comprehensive quality control and inspection system. At the same time, it has continuously innovated and laid out multiple patents, including synthetic routes, process optimization, and separation crystallization purification, forming a core patent group that controls key technologies.
COSYCHEM has the capability for the development and production of upstream raw materials in the nucleic acid drug industry chain, providing key raw materials required for the synthesis of nucleic acid sequences by pharmaceutical companies engaged in the development of nucleic acid drugs. This includes standard phosphoramidites and modified phosphoramidite monomers, modified nucleotides, NTPs, cap analogs, and other key raw materials, as well as customized development services. It addresses the issues that restrict industry development from the source, achieving the quality stability and production capacity stability of nucleic acid drug raw materials.
Founder of COSYCHEM, Song Yanmin, said that COSYCHEM has been accumulating technology for more than a decade and has continuously expanded its business boundaries based on this, forming a comprehensive business pattern of characteristic pharmaceutical intermediate raw materials + diagnostic analytical chemical raw materials + nucleic acid drug chemical raw materials + innovative small nucleic acid drugs. The company is currently at a historical opportunity period, with a vigorous development of downstream products. COSYCHEM will continue to maintain a leading position in core technology, intensify the development of cutting-edge raw materials, and create a highland of nucleic acid chemical raw materials.
General Manager of Cohesive Energy Investment, Ma Lei, said that molecular biology has driven a major explosion of life science research achievements over the past thirty years. We have seen the rapid rise of small nucleic acid drugs and mRNA drugs in recent years, which are expected to become the third major form of drugs. We firmly believe in the prospects of nucleic acid drugs. COSYCHEM has more than a decade of technical experience accumulation and sufficient product reserves, with a steady business growth. Over the past few years, it has quickly established a solid industry customer base, and both its technology and products have been recognized for commercialization.